How many investments has Easton Capital made?

Easton Capital has 25 tracked investments, 3 of which have exited, including 3 dated in the last 24 months.

What stage does Easton Capital invest at?

Easton Capital invests at the Seed, Series A, Series B, Late Stage stages.

What is Easton Capital's typical check size?

Easton Capital typically writes checks of $10M – $20M.

What sectors does Easton Capital focus on?

Easton Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Where is Easton Capital located?

Easton Capital is headquartered in New York, US.

Who does Easton Capital co-invest with?

Easton Capital most often shares deals with ARCH Venture Partners, Kaiser Permanente Ventures, Lightspeed Venture Partners, among 12 tracked co-investors.

Easton Capital

Venture capital

New York · Seed–Late Stage · 7 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Easton Capital

93 people in our graph share verified history with the Easton Capital team — schools, employers, funds. One of them is your warm intro.

Dan Moreheadunlockedknows Richard Lipkin · together at Princeton University (overlapped)

×8knows the team · via Princeton University

×3knows the team · via Columbia Business School

✨ Fox Verdict

Investment thesis

Easton Capital takes a classical view of venture capital, investing exclusively in healthcare and life sciences opportunities that can materially improve care or lower its cost. It favors capital-efficient business models that typically need no more than an additional $10-20 million to reach market and become cash-flow positive or be acquired. Deals are structured to maximize returns and minimize risk across all economic environments, keeping the capital base low and dilution minimal to align interests with entrepreneurs. The team spans science, technology, clinical affairs, investment, operations, and business development, and the firm actively supports non-traditional and female founders.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices New York New York City United States

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Late Stage

Check

$10M – $20M

New York, New York, US

Instruments

Equity

Founded

1999

Last 12 months

3 investments

AUM

$200M

Tracked investments

Acquisitions

Team · 7 people

from the firm's website & public directories

Kresmir Letinic· Managing Director

k•••@eastoncapital.comreveal

Charles Hughes· III, Managing Director

h•••@eastoncapital.comreveal

Francisco Garcia· Managing Director

Frank Garcia is a Managing Director at Easton Capital, which he joined in 2000, with over twenty-five years of experience as a principal investor and investment banker. He previously headed Corporate Finance at Cramer Rosenthal McGlynn, ran Neptune Management Company, and held roles at Kidder, Peabody & Co. and as an attorney at Sullivan & Cromwell. He holds a JD from Harvard Law School and an AB from Harvard College.

g•••@eastoncapital.comreveal

John Friedman· Managing Partner· New York, New York, United Statesin

f•••@eastoncapital.comreveal

Kresimir Letinic· Managing Director· Palo Alto, California, United Statesin

Kresimir Letinic, MD, PhD, is a Managing Director at Easton Capital, which he joined in 2009, where he built and leads the firm's Healthcare IT practice. Before Easton, he was a Howard Hughes Medical Institute Predoctoral Fellow at Yale University and worked at Fletcher Spaght Ventures, The Channel Group, and Lesanne Life Sciences. His work focuses on health information technology, biotech, diagnostics, and medical devices, and he is a Kauffman Fellow (class 15).

Richard Lipkin· Managing Director· New York City Metropolitan Areain

Richard Lipkin is a Managing Director of Easton. He previously was a partner at Commerce Health Ventures, a life sciences healthcare fund, and at Laird & Co., a private merchant bank, worked as a biotech analyst consultant for a Goldman Sachs hedge fund and for DARPA, and served as Executive Director of the Strang Cancer Prevention Center. He is an honors graduate of Princeton University, holds an MBA from Columbia, studied theoretical neuroscience at Columbia University, and is a Senior Staff Associate in Columbia's Department of Neuroscience.

r•••@eastoncapital.comreveal

Ting Pau Oei· Executive Partner

Ting Pau Oei is Executive Partner at Easton Capital, with over 30 years in the healthcare industry, including 22 years at Johnson & Johnson in operating and investing roles. He co-managed Johnson & Johnson Development Corp., where he oversaw more than 40 investments in biopharmaceutical, diagnostic, and health information technology companies, and previously led Ortho Pharmaceutical International. Earlier in his career he held positions at Abbott Laboratories and Merck.

t•••@eastoncapital.comreveal

What they invest in

from 10 of 25 portfolio companies

Healthtech ×6Biotech ×4AI & Machine Learning ×2AdTech ×1Digital Health ×1E-commerce ×1Enterprise Software ×1FemTech ×1

HQs:United States×10Canada×1

Investments · 25 tracked

founders shown can be your intro path

By year:2026 · 3 2021 · 1 2019 · 1 2014 · 2 2012 · 18 dated

Bluebird Biobluebirdbio.com in 𝕏Sep 2021Acquired

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)

Co-investorsARCH Venture Partners RA Capital Sanofi Ventures

Claret Medicalclaretmedical.comAug 2014

HealthtechSanta Rosa, US

Fred Khosravi(Director)Tony Fields(Executive Officer)

BoardJames Eadie(Director)Azin Parhizgar(Executive Officer, Director)inHenry A. Plain(Director)Leo Nelson Hopkins(Director)

Co-investors415 Capital Lightstone Ventures

Comprehendcomprehend.com 𝕏Feb 2019Acquired

Comprehend develops software for clinical trial operations teams to consolidate and analyze trial data from multiple sources in real-time, helping them move treatments through clinical testing more efficiently and safely.

HealthtechSaaSSan Francisco, US

Rick Morrison(Founder/CEO)inPaul Judson Gardner(Executive Officer, Director)Richard V Morrison, Jr.(Executive Officer, Director)Terence Cunningham(Executive Officer, Director)

BoardMike Dixon(Director)Kristopher Koka(Director)

Co-investorsLightspeed Venture Partners Y Combinator Crosslink Capital Sequoia Capital SV Angel

Emkineticsemkinetics.comFeb 2014

San Francisco, US

Daniel Burnett(Director)Richard John Faleschini(Executive Officer)

BoardKevin Patrick Finney(Director)Hugh L. Narciso, Jr.(Director)Jordan Carter Meyer(Director)

Kit Checkkitcheck.com in

Bluesight provides software solutions for hospital and pharmacy operations, including inventory management, drug diversion monitoring, purchasing optimization, and compliance tools.

AI & Machine LearningEnterprise SoftwareHealthtechWashington, US

Kevin MacDonald(Executive Officer)inTimothy Kress-Spatz(Executive Officer)

Co-investorsKaiser Permanente Ventures LionBird Rex Health Ventures New Leaf Venture Partners Rock Health

Precise Light Surgicalpreciselightsurgical.com

Campbell, US

Richard Nash(Chief Executive Officer)

Board John Friedman(Director)inPeter Scull(Director)Marc Russo(Director)Peter Hadrovic(Director)Willem Volschenk(Director)

Co-investorsSouthern Cross Venture Partners

Promediorpromedior.comFeb 2012

BiotechMalvern, US

Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)

BoardJames W. Broderick, M.D.(Director)Geert-Jan Mulder(Director)in John Friedman(Director)inHarold R. Werner(Director)

Co-investorsSofinnova Ventures Easton Capital Investment Group Forbion

Resolve Therapeuticsresolvetherapeutics.com

Biopharma company developing non-immunosuppressive drugs for autoimmune diseases.

James Posada, Ph.D.(Founder)in

Co-investorsNew Science Ventures WRF Capital

Respiratory Motionrespiratorymotion.com

HealthtechWaltham, US

Jenny Freeman(Executive Officer, Director)inKamen Bliznashki(Executive Officer)Svetlana Panasyuk(Executive Officer)

BoardJaideep Mehta(Director)Peter Aranow(Director)Don Freeman(Director)

Co-investorsBoston Harbor Angels Keiretsu Forum OSF Ventures Walnut Venture Associates

Trellisgotrellis.com inJul 2026 · $9M

Trellis is an AI-driven platform that automates advertising, pricing, and profitability optimization for eCommerce sellers on marketplaces like Amazon, Walmart, and Shopify.

AdTechAI & Machine LearningE-commerceOttawa, CA

Denis Leclair(Founder)in Fahim Sheikh(Founder)in

Co-investorsSentiero Ventures AMR Action Fund Craft Ventures New Science Ventures Okapi Venture Capital Stout Street Capital

Trellisjointrellishealth.com inJul 2026 · $9M

Trellis Health provides personalized health insights that track individual changes over time rather than comparing against population norms.

Digital HealthFemTechHealthtech

Co-investorsPALETTE VENTURES Swizzle Ventures AMR Action Fund New Science Ventures

Trellisbiotrellisbio.com in

Trellis Bioscience develops human monoclonal antibody therapeutics targeting bacterial, viral, and cancer indications.

BiotechHealthtech

Co-investorsAMR Action Fund New Science Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

AcordaConor MedsystemsCordisElectrocoremedicalMediklyPerceptimedResolvebioSgrouplesShimojaniSolxTigertextTrellis BioscienceWithin3

Exits · 3

3 acquisitions · showing 1

Conor Medsystemsacq. by Johnson & Johnson

Portfolio news

latest coverage across their companies

The $9M push to crack prosthetic joint infections - Becker’s Spine Review

Trellis Bioscience · beckersspine.com · Jul 20, 2026

Trellis Bioscience Raises $9M in Series C Funding

Trellis · finsmes.com · Jul 20, 2026

Trellis Bioscience Raises $9M in Series C Funding

Trellis · finsmes.com · Jul 20, 2026

Sell or Invest in Precise Light Surgical Stock Pre-IPO

Precise Light Surgical · nasdaqprivatemarket.com · Oct 21, 2025

Frequently asked questions

How many investments has Easton Capital made?: Easton Capital has 25 tracked investments, 3 of which have exited, including 3 dated in the last 24 months.
What stage does Easton Capital invest at?: Easton Capital invests at the Seed, Series A, Series B, Late Stage stages.
What is Easton Capital's typical check size?: Easton Capital typically writes checks of $10M – $20M.
What sectors does Easton Capital focus on?: Easton Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Easton Capital located?: Easton Capital is headquartered in New York, US.
Who does Easton Capital co-invest with?: Easton Capital most often shares deals with ARCH Venture Partners, Kaiser Permanente Ventures, Lightspeed Venture Partners, among 12 tracked co-investors.

Images

Similar investors

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

JAZZ Venture Partners

JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.

$100K – $20M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Gore Range Capital

Gore Range Capital is a specialized healthcare investment firm building science-led platforms across precision health, regenerative medicine, personalized therapeutics, and longevity. It provides strategic, financial, and clinical guidance to portfolio companies developing next-generation healthcare solutions.

$500K – $5M